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tp://dx.doi.org/10.1016/j.hjc.2016
09-9666/ª 2016 Hellenic Cardiologi
ense (http://creativecommons.org/Acetylsalicylic acid (ASA) represents a standard part of dual
antiplatelet treatment with clopidogrel in patients with
coronary artery disease (CAD) undergoing percutaneous
coronary intervention (PCI) with stent placement.1 In
certain patients, high residual platelet reactivity is highly
correlated with aspirin resistance. Therefore, our study was
focused on the prevalence of high on-treatment platelet
reactivity, due to aspirin resistance in patients with coro-
nary artery disease after PCI with stent placement, and
evaluation of any difference in prevalence by the presence
of metabolic syndrome and/or type 2 diabetes mellitus.2
The study was conducted in Belgrade at the Cardiology
Clinic, Clinical Center of Serbia. We enrolled 90 adult pa-
tients (62 male, 28 female; mean age 63 12 years) with
CAD who underwent PCI with stent placement (BMS, DES or
BMS þ DES). All patients signed a written informed consent
to participate in the study, according to the study protocols
approved by the institutional commission for postgraduate
studies of the University of Belgrade, School of Medicine.
The first patient was enrolled in August 2010, and the last
patient was enrolled in December 2012. All patients were
already on aspirin treatment (100 mg/day) prior to PCI and
continued with the same dosing after successful PCI. Clo-
pidogrel was administered in a 600 mg loading dose prior to
PCI and continued in a 75 mg daily dose after successful PCI
according to standard dual antiplatelet treatment guide-
lines. Patients with stable coronary artery disease were
included, and 69 patients (77%) had a history of previous
myocardial infarction. All patients were enrolled in ay of Hellenic Cardiological
.05.006
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).prospective consecutive manner, until the minimum esti-
mated number for statistical power of the study of 30
subjects in the control group and 60 subjects in the car-
diometabolic risk group was reached. Patients were then
divided into three groups based on: absence (control group)
or presence of metabolic syndrome (MetSy) and type 2
diabetes mellitus as follows: group 1 included 30 patients
without MetSy and without type 2 diabetes mellitus; group
2 included 33 patients with MetSy, and no type 2 diabetes
mellitus; group 3 included 27 patients with MetSy and type
2 diabetes mellitus. The diagnosis of MetSy was set ac-
cording to NHLBI Adult Treatment Panel III (ATP III)3 and
type 2 diabetes mellitus was diagnosed in patients with
morning blood glucose level 7.0 mmol/l or patients on
active DM therapy.
We evaluated platelet reactivity with a whole blood
impedance aggregometer, by testing responsiveness to
aspirin using ASPI-test (aspirin-test with arachidonic acid as
activating agent). For responsiveness to clopidogrel, ag-
gregation was measured using a high-sensitivity ADPtest
(combination of ADP and prostaglandin E1). This combina-
tion is used to enhance sensitivity to the effects of clopi-
dogrel on ADP-induced platelet activation. PGE1 reduces
intracellular calcium mobilization, and therefore platelet
activation, thus acting synergistically with the clopidogrel
effect. Multielectrode platelet analyzer is a widely used
point-of-care test for the estimation of platelet reactivity.4
All subjects reported ingestion of an ASA tablet in the
morning on the day of the intervention (4 to 7 hours before
intervention). Approximately 30 minutes after successful
PCI with stent(s) implanted, 5 mL of whole blood from
antecubital vein was sampled in a vacutainer tube. After a
30-min sample homogenization period, and 3-min stirring
with saline solution pre-warmed to 37C, the reactivity
measurement was performed in a single-use test cell with
two pairs of electrodes (two separate impedance sensors)
over 6 minutes. Analyzer’s software transforms data into
aggregatory units, plotting values as two separate aggre-
gation curves against time, for each pair of electrodes. The
result for each sample tested was expressed as AUC (area
under the curve), representing AU*min (aggregatory units
per minute). Aspirin resistance was defined as a test resultElsevier B.V. This is an open access article under the CC BY-NC-ND
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as a test result value equal to and above 468 AUC.6 The
mean duration of follow-up period was 11 months (SDZ 3).
Major adverse cardiovascular event (MACE) was defined as:
clinically manifested myocardial infarction (MI), revascu-
larization procedure in same vessel, cerebrovascular insult
(CVI), and MACE-related death. Discrete data were sum-
marized as frequencies and continuous data were summa-
rized as the mean SD. The chi-square test was used for
comparison of categorical variables, and the two-tailedTable 1 Participants’ clinical characteristics.
All
n/(%) 90
Age (years) 63
Male 62 (68.9)
Female 28 (31.1)
Body weight in kg 81.4
Body mass Index in kg/m2 27.1
Waist circumference in cm 98.9
Triglycerides mmol/l 1.89
HDL mmol/l 1.16
Blood glucose mmol/l 6.52
Blood pressure mmHg systolic 131.4
diastolic 81.4
Ejection fraction (EF%) 54.2
mean AUC aspirin 251
clopidogrel 371
aspirin resistance 6 (6.7)
clopidogrel resistance 34 (37.8)
Previous myocardial infarction 69 (76.7)
Previous intervention PCI 22 (24.4)
CABG 2 (2.2)
Pacemaker 1 (1.1)
Abdominal obesity 53 (58.9)
Hypertension 79 (87.8)
Hyperlipidemia 70 (77.8)
Diabetes mellitus 27 (30.0)
Current medication statin 57 (63.3)
b-blocker 37 (41.1)
ACE inhibitor/ARB 47 (52.2)
Ca-antagonists 9 (10.0)
nitrates 42 (46.7)
diuretics 14 (15.6)
IPP/H2-antagonist 23 (25.6)
oral antidiabetic 24 (26.7)
Smoking Non smoker 39 (43.3)
Ex-smoker 23 (25.6)
Active smoker 28 (31.1)
Stent type BMS 51 (56.7)
DES 34 (37.8)
BMS + DES 5 (5.6)
Follow-up Myocardial infarction 12 (13.3)
Revascularization 19 (21.1)
CVI 0
Cardiac death 2 (2.2)
MACE 33 (36.7)
n/(%) stands for numbers in columns/ parentheses.
Clinically significant differences are represented in italics.Student’s t test was used to test differences among
continuous variables. Dichotomous platelet reactivity vari-
ables, according to aspirin resistance criteria were used. A
value of p< 0.05 was considered to be significant. All sta-
tistical analyses were performed using SPSS software,
version 17.0 (SPSS Inc., Chicago, Illinois, USA). There were
no significant differences between groups regarding age,
gender, previous myocardial infarction, previous in-
terventions or current pharmacological treatment. Data on
baseline clinical characteristics of the patients and majorGroup 1 Group 2 Group 3 p-value
30 33 27
64 62 63 .256
23 (76.7) 21 (63.6) 18 (66.7) .513
7 (23.3) 12 (36.4) 9 (33.3)
78.6 80.6 85.5 .431
25.1 27.3 28.1 .032
93.6 101.3 101.8 <0.001
1.53 1.85 2.19 .120
1.26 1.13 1.14 .392
5.44 5.38 8.42 .030
134.3 126.5 133.4 .263
84.5 79.0 80.5 .045
52.0 54.8 55.5 .368
276 269 201.6 .378
343 392 375.5 .351
0 4 (12.1) 2 (7.4) .154
6 (10.0) .065
12 (40.0) 14 (42.4) 8 (29.6) .569
24 (80.0) 26 (78.8) 19 (70.4) .574
7 (23.3) 10 (30.3) 5 (18.5) .655
0 1 (3.0) 1 (3.7)
1 (3.3) 0 0
6 (20.0) 26 (78.8) 21 (77.8) <0.001
20 (66.7) 32 (97.0) 27 (100.0) <0.001
18 (60.0) 30 (90.9) 22 (81.5) 0.011
0 0 27 (100.0) <0.001
17 (56.7) 22 (66.7) 18 (66.7) .650
9 (30.0) 13 (39.4) 15 (55.6) .142
15 (50.0) 16 (48.5) 16 (59.3) .677
3 (10.0) 5 (15.2) 1 (3.7) .339
12 (40.0) 18 (54.5) 12 (44.4) .494
2 (6.7) 6 (18.2) 6 (22.2) .236
8 (26.7) 7 (21.2) 8 (29.6) .747
0 (0.0) 0 (0.0) 24 (88.9) <0.001
13 (43.3) 10 (30.3) 16 (59.3) .116
8 (26.7) 8 (24.2) 7 (25.9)
9 (30.0) 15 (45.5) 4 (14.8)
15 (50.0) 21 (63.6) 15 (55.6) .814
13 (43.3) 10 (30.3) 11 (40.7)
2 (6.7) 2 (6.1) 1 (3.7)
4 (13.3) 5 (15.2) 3 (11.1) .900
5 (16.7) 7 (21.2) 7 (25.9) .694
0 0 0 e
1 (3.3) 1 (3.0) 0 .570
10 (33.3) 13 (39.4) 10 (37.0) .570
Table 2 Cardiovascular risk factors, aspirin resistance
and clopidogrel resistance.
Cardiovascular
risk factor
presence
Aspirin resistance p-value
No n(%) Yes n(%)
Arterial
hypertension
No 11 (12.2) 0 (0) .344
Yes 73 (81.1) 6 (6.7)
Lipid disorder No 20 (22.2) 0 (0) .175
Yes 64 (71.1) 6 (6.7)
Glycemia
disorder
No 59 (65.6) 4 (4.4) .154
Yes 25 (27.8) 2 (2.2)
Abdominal
obesity
No 37 (41.1) 0 (0) .034
Yes 47 (52.2) 6 (6.7)
Tobacco
smoking
Non-smoker 36 (40.0) 3 (3.3) .872
Ex-smoker 22 (24.4) 1 (1.1)
Active
smoker
26 (28.9) 2 (2.2)
Clopidogrel
resistance
No 54 (60.0) 2 (2.2) .131
Yes 30 (33.3) 4 (4.4)
Clinically significant differences are represented in italics.
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marized in Table 1. The three groups of subjects signifi-
cantly differed by the presence of MetSy and/or T2DM
(p< 0.005). We investigated the relationship between
cardiovascular risk factors and aspirin resistance. Abdom-
inal obesity was the only risk factor significantly (pZ .034)
associated with a positive finding of aspirin resistance
(Table 2).
High residual platelet reactivity related to aspirin resis-
tance was a more frequent finding in patients with coex-
isting cardiovascular risk factors, such as MetSy, with or
without T2DM. Although the more frequent finding of aspirin
resistance in our study coincides with the shorter MACE-free
survival period in some groups of patients, we did not find
aspirin resistance to be the single predicting factor for
MACE(s) during the follow-up period; a finding recently re-
ported by others.7,8 Patients with metabolic syndrome and
diabetes mellitus demonstrated a higher rate of MACE,
particularly revascularization after stent placement. A weak
platelet response to aspirin treatment could be expected in
subjects with several known, coexisting cardiovascular risk
factors, due to the load of platelet aggregation stimuli in the
circulating blood of patients with T2DM, or patients with
coronary blood vessel pathology. These results imply that
the coexistence of several cardiovascular risk factors
(elevated blood pressure, elevated blood lipid levels,
elevated blood sugar levels and abdominal obesity) can lead
to the presence of high platelet reactivity after standard
aspirin dosing, and a shorter MACE-free survival period after
PCI. These findings from our study may indicate a possible
interaction between circulating proinflammatory agents,
the presence of metabolically active abdominal fat de-
posits, and ingested aspirin, causing low responsiveness to
treatment. Clopidogrel resistance was registered more
frequently; 37.8% overall in subjects, but with no significant
between-group differences (pZ .569). Although four out of
the six non-responders to aspirin were concomitantly non-
responders to clopidogrel therapy, this relationship wasnot significant (pZ .131), nor was there an increase in MACE
documented for these patients. Several studies have shown
the health implications of excessive fat tissue deposit
localization, especially abdominal (visceral) fat, in contrast
to subcutaneous, demonstrating a significant relationship
with the increased risk of various disease development.9
Waist circumference, one of the most comfortable ways to
estimate increased abdominal fat deposits, can be routinely
measured during regular check-ups as a vital parameter,
similar to arterial blood pressure measurement or body mass
index estimation.10
High residual platelet reactivity, despite dual anti-
platelet therapy, is a more prevalent finding in patients
with prominent cardiometabolic risk profiles. In such pa-
tients, cardiovascular risk evaluation and an individualized
approach to antiplatelet treatment should be considered to
be options after successful coronary intervention.
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